The Vero cell line is considered the most used continuous cell line for the production of viral vectors and vaccines. Historically, it is the first cell line that was approved by the WHO for the production of human vaccines. Comprehensive experimental data on the production of many viruses using the Vero cell line can be found in the literature. However, the vast majority of these processes is relying on the microcarrier technology. While this system is established for the large-scale manufacturing of viral vaccine, it is still quite complex and labor intensive. Moreover, scale-up remains difficult and is limited by the surface area given by the carriers. To overcome these and other drawbacks and to establish more efficient manufacturing processes, it is a priority to further develop the Vero cell platform by applying novel bioprocess technologies. Especially in times like the current COVID-19 pandemic, advanced and scalable platform technologies could provide more efficient and cost-effective solutions to meet the global vaccine demand.

Herein, we review the prevailing literature on Vero cell bioprocess development for the production of viral vectors and vaccines with the aim to assess the recent advances in bioprocess development. We critically underline the need for further research activities and describe bottlenecks to improve the Vero cell platform by taking advantage of recent developments in the cell culture engineering field.

Vero细胞系被认为是生产病毒载体和疫苗最常用的连续细胞系。从历史上看，它是世卫组织批准用于生产人疫苗的第一个细胞系。关于使用Vero细胞系生产许多病毒的综合实验数据，可以在文献中找到。但是，这些过程中的绝大多数都依赖于微载体技术。虽然该系统是为大规模生产病毒疫苗而建立的，但它仍然相当复杂且劳动强度大。而且，按比例放大仍然很困难，并且受到载体给定的表面积的限制。为了克服这些和其他缺点并建立更有效的制造工艺，优先考虑通过应用新型生物工艺技术进一步开发Vero细胞平台。

本文中，我们回顾了有关Vero细胞生物过程开发中用于生产病毒载体和疫苗的主流文献，目的是评估生物过程开发中的最新进展。我们严格地强调了进一步研究活动的必要性，并描述了利用细胞培养工程领域的最新发展来改善Vero细胞平台的瓶颈。